Cathepsins and their involvement in immune responses

Swiss Medical Weekly

Volumn 140, Issue JULY, 2010, Pages

  Conus, Sébastien ^a   Simon, Hans Uwe ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Adaptive and innate immunity; Apoptosis; Cathepsin; Immune response; Lysosome

Indexed keywords

CATHEPSIN; CATHEPSIN B; CATHEPSIN D; CATHEPSIN K; CATHEPSIN L; CATHEPSIN S; CYSTEINE PROTEINASE; CYTOKINE; LYSOSOME ENZYME; SERINE PROTEINASE; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; APOPTOSIS; CELL DAMAGE; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; INFLAMMATORY CELL; INNATE IMMUNITY; LOSS OF FUNCTION MUTATION; LYSOSOME; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 82755167524     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2010.13042     Document Type: Review

References (99)

1. Conus S, Simon H-U. Cathepsins: key modulators of cell death and inflammatory responses. Biochem Pharmacol. 2008;76(11):1374-82.
2. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med. 1989;320(6):365-77.
3. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature. 2000;407(6805):784-8.
4. Simon H-U. Neutrophil apoptosis pathways and their modifications in inflammation. Immunol Rev. 2003;193(1):101-10. (Pubitemid 36688044)
5. Lamkanfi M, Festjens N, Declercq W, Berghe TV, Vandenabeele P. Caspases in cell survival, proliferation and differentiation. Cell Death Differ. 2006;14(1):44-55.
6. Turk B, Turk D, Turk V. Lysosomal cysteine proteases: more than scavengers. Biochem Biophys Acta. 2000;1477(1-2):98-111. (Pubitemid 30119895)
7. Foghsgaard L, Wissing D, Mauch D, Lademann U, Bastholm L, Boes M, et al. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J Cell Biol. 2001;153(5):999-1010.
8. Guicciardi ME, Miyoshi H, Bronk SF, Gores GJ. Cathepsin B knockout mice are resistant to tumor necrosis factor-{alpha}-mediated hepatocyte apoptosis and liver injury: implications for therapeutic applications. Am J Pathol. 2001;159(6):2045-54. (Pubitemid 33104259)
9. Salvesen GS. A lysosomal protease enters the death scene. J Clin Invest. 2001;107(1):21-3.
10. Roberg K, Kagedal K, Ollinger K. Microinjection of cathepsin D induces caspase-dependent apoptosis in fibroblasts. Am J Pathol. 2002;161(1):89-96. (Pubitemid 34760774)
11. Turk B, Stoka V, Rozman-Pungercar J, Cirman T, Droga-Mazovec G, Oresic K, et al. Apoptotic pathways: involvement of lysosomal proteases. Biol Chem. 2002;383:1035-44. (Pubitemid 35215049)
12. Lockshin RA, Zakeri Z. Caspase-independent cell death? Oncogene. 2004;23(16):2766-73. (Pubitemid 38638840)
13. Friedrichs B, Tepel C, Reinheckel T, Deussing J, von Figura K, Herzog V, et al. Thyroid functions of mouse cathepsins B, K, and L. J Clin Invest. 2003;111(11):1733-45. (Pubitemid 38057754)
14. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des. 2007;13:387-403. (Pubitemid 46477760)
15. Holt OJ, Gallo F, Griffiths GM. Regulating secretory lysosomes. J Biochem. 2006;140(1):7-12. (Pubitemid 44433540)
16. Dell'Angelica EC, Mullis C, Caplan S, Bonifacino JS. Lysosome-related organelles. FASEB J. 2000;14(10):1265-78. (Pubitemid 30439735)
17. Blott EJ, Griffiths GM. Secretory lysosomes. Nat Rev Mol Cell Biol. 2002;3(2):122-31.
18. Turk V, Turk B, Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J. 2001;20(17):4629-33. (Pubitemid 32848615)
19. Rossi A, Deveraux Q, Turk B, Sali A. Comprehensive search for cysteine cathepsins in the human genome. Biol Chem. 2004;385(5):363-72. (Pubitemid 38787114)
20. Barrett AJ, Rawlings ND, Woessner JF. Handbook of proteolytic enzymes. (New York, USA: Academic Press) 2004.
21. Zavasnik-Bergant T, Turk B. Cysteine cathepsins in the immune response. Tissue Antigens. 2006;67(5):349-55.
22. Turk B, Turk D, Salvesen GS. Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr Pharm Des. 2002;8(18):1623-37. (Pubitemid 34752830)
23. Chwieralski CE, Welte T, Bühling F. Cathepsin-regulated apoptosis. Apoptosis. 2006;11(2):143-9. (Pubitemid 43291015)
24. Zavasnik-Bergant T, Turk B. Cysteine proteases: destruction ability versus immunomodulation capacity in immune cells. Biol Chem. 2007;388(11):1141-9. (Pubitemid 350059624)
25. Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C, et al. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest. 2000;106(9):1127-37.
26. Stoka V, Turk B, Schendel SL, Kim TH, Cirman T, Snipas SJ, et al. Lysosomal protease pathways to apoptosis. Cleavage of Bid, not procaspases, is the most likely route. J Biol Chem. 2001;276(5):3149-57.
27. Li W, Yuan X, Nordgren G, Dalen H, Dubowchik GM, Firestone RA, et al. Induction of cell death by the lysosomotropic detergent MSDH. FEBS Lett. 2000;470(1):35-9. (Pubitemid 30155619)
28. Boya P, Andreau K, Poncet D, Zamzami N, Perfettini J-L, Metivier D, et al. Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med. 2003;197(10):1323-34. (Pubitemid 36617779)
29. Conus S, Perozzo R, Reinheckel T, Peters C, Scapozza L, Yousefi S, et al. Caspase-8 is activated by cathepsin D initiating neutrophilapoptosis during the resolution of inflammation. J Exp Med. 2008;205(3):685-98. (Pubitemid 351439313)
30. Blomgran R, Zheng L, Stendahl O. Cathepsin-cleaved Bid promotes apoptosis in human neutrophils via oxidative stress-induced lysosomal membrane permeabilization. J Leukoc Biol. 2007;81(5):1213-23. (Pubitemid 46702040)
31. Asagiri M, Hirai T, Kunigami T, Kamano S, Gober H-J, Okamoto K, et al. Cathepsin K-dependent Toll-like receptor 9 signalling revealed in experimental arthritis. Science. 2008;319(5863):624-7. (Pubitemid 351197065)
32. Matsumoto F, Saitoh S, Fukui R, Kobayashi T, Tanimura N, Konno K, et al. Cathepsins are required for Toll-like receptor 9 responses. Biochem Biophys Res Commun. 2008;367(3):693-9.
33. Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi G-P, Chapman HA, et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature. 2008;456(7222):658-62.
34. Park B, Brinkmann MM, Spooner E, Lee CC, Kim Y-M, Ploegh HL. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat Immunol. 2008;9(12):1407-414.
35. Padrines M, Wolf M, Walz A, Baggiolini M. Interleukin-8 processing by neutrophil elastase, cathepsin G and proteinase-3. FEBS Lett. 1994;352(2):231-5. (Pubitemid 24298425)
36. Bank U, Küpper B, Reinhold D, Hoffmann T, Ansorge S. Evidence for a crucial role of neutrophil-derived serine proteases in the inactivation of interleukin-6 at sites of inflammation. FEBS Lett. 1999;461(3):235-40. (Pubitemid 29533339)
37. Ohashi K, Naruto M, Nakaki T, Sano E. Identification of interleukin-8 converting enzyme as cathepsin L. Biochem Biophys Acta. 2003;1649(1):30-9. (Pubitemid 38234592)
38. Ha S-D, Martins A, Khazaie K, Han J, Chan BM, Kim SO. Cathepsin B is involved in the trafficking of TNF-{alpha}-containing vesicles to the plasma membrane in macrophages. J Immunol. 2008;181(1):690-7.
39. Meyer-Hoffert U. Neutrophil-derived serine proteases modulate innate immune responses. Front Biosci. 2009;14:3409-18.
40. Colbert JD, Matthews SP, Miller G, Watts C. Diverse regulatory roles for lysosomal proteases in the immune response. Eur J Immunol. 2009;39(11):2955-65.
41. Salvesen G, Enghild JJ. An unusual specificity in the activation of neutrophil serine proteinase zymogens. Biochemistry. 1990;29(22):5304-8. (Pubitemid 20193935)
42. Adkison AM, Raptis SZ, Kelley DG, Pham CT. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest. 2002;109(3):363-71. (Pubitemid 34141810)
43. Mallen-St. Clair J, Pham CT, Villalta SA, Caughey GH, Wolters PJ. Mast cell dipeptidyl peptidase I mediates survival from sepsis. J Clin Invest. 2004;113(4):628-34.
44. Methot N, Guay D, Rubin J, Ethier D, Ortega K, Wong S, et al. In vivo inhibition of serine protease processing requires a high fractional inhibition of cathepsin C. Mol Pharmacol. 2008;73(6):1857-65. (Pubitemid 351724373)
45. Honey K, Rudensky AY. Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol. 2003;3(6):472-82. (Pubitemid 37339187)
46. Villadangos JA, Schnorrer P, Wilson NS. Control of MHC class II antigen presentation in dendritic cells: a balance between creative and destructive forces. Immunol Rev. 2005;207(1):191-205. (Pubitemid 41415018)
47. Chapman HA. Endosomal proteases in antigen presentation. Curr Opin Immunol. 2006;18(1):78-84. (Pubitemid 43049652)
48. Nakagawa TY, Brissette WH, Lira PD, Griffiths RJ, Petrushova N, Stock J, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity. 1999;10(2):207-17. (Pubitemid 29115626)
49. Shi G-P, Villadangos JA, Dranoff G, Small C, Gu L, Haley KJ, et al. Cathepsin S required for normal MHC Class II peptide loading and germinal center development. Immunity. 1999;10(2):197-206. (Pubitemid 29115625)
50. Reich M, van Swieten PF, Sommandas V, Kraus M, Fischer R, Weber E, et al. Endocytosis targets exogenous material selectively to cathepsin S in live human dendritic cells, while cell-penetrating peptides mediate nonselective transport to cysteine cathepsins. J Leukoc Biol. 2007;81(4):990-1001. (Pubitemid 46495648)
51. Driessen C, Bryant RA, Lennon-Dumenil A-M, Villadangos JA, Bryant PW, Shi G-P, et al. Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells. J Cell Biol. 1999;147(4):775-90.
52. Nakagawa T, Roth W, Wong P, Nelson A, Farr A, Deussing J, et al. Cathepsin L: critical role in li degradation and CD4 T cell selection in the thymus. Science. 1998;280(5362):450-3. (Pubitemid 28208170)
53. Tolosa E, Li W, Yasuda Y, Wienhold W, Denzin LK, Lautwein A, et al. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J Clin Invest. 2003;112(4):517-26. (Pubitemid 38056336)
54. Kakehashi H, Nishioku T, Tsukuba T, Kadowaki T, Nakamura S, Yamamoto K. Differential regulation of the nature and functions of dendritic cells and macrophages by cathepsin E. J Immunol. 2007;179(9):5728-37.
55. Burster T, Reich M, Zaidi N, Voelter W, Boehm BO, Kalbacher H. Cathepsin E regulates the presentation of tetanus toxin C-fragment in PMA activated primary human B cells. Biochem Biophys Res Commun. 2008;377(4):1299-303.
56. Savina A, Jancic C, Hugues S, Guermonprez P, Vargas P, Moura IC, et al. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell. 2006;126(1):205-18. (Pubitemid 44026552)
57. Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science. 2005;307(5715):1630-4. (Pubitemid 40354746)
58. Zou J, Henderson L, Thomas V, Swan P, Turner AN, Phelps RG. Presentation of the goodpasture autoantigen requires proteolytic unlocking steps that destroy prominent T cell epitopes. J Am Soc Nephrol. 2007;18(3):771-9. (Pubitemid 46434494)
59. Manoury B, Mazzeo D, Fugger L, Viner N, Ponsford M, Streeter H, et al. Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP. Nat Immunol. 2002;3(2):169-74. (Pubitemid 34141447)
60. Burster T, Beck A, Tolosa E, Marin-Esteban V, Rotzschke O, Falk K, et al. Cathepsin G, and not the asparagine-specific endoprotease, controls the processing of myelin basic protein in lysosomes from human B lymphocytes. J Immunol. 2004;172(9):5495-503. (Pubitemid 38542050)
61. Fiebiger E, Meraner P, Weber E, Fang IF, Stingl G, Ploegh H, et al. Cytokines regulate proteolysis in major histocompatibility complex class II-dependent antigen presentation by dendritic cells. J Exp Med. 2001;193(8):881-92. (Pubitemid 32525861)
62. Drakesmith H, O'Neil D, Schneider SC, Binks M, Medd P, Sercarz E, et al. In vivo priming of T cells against cryptic determinants by dendritic cells exposed to interleukin 6 and native antigen. Proc Natl Acad Sci. USA 1998;95(25):14903-8. (Pubitemid 29003729)
63. Sendide K, Deghmane A-E, Pechkovsky D, Av-Gay Y, Talal A, Hmama Z. Mycobacterium bovis BCG attenuates surface expression of mature class II molecules through IL-10-dependent inhibition of cathepsin S. J Immunol. 2005;175(8):5324-32. (Pubitemid 41456418)
64. Pham CT, Ley TJ. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc Natl Acad Sci. USA 1999;96(15):8627-32. (Pubitemid 29354842)
65. Sutton VR, Waterhouse NJ, Browne KA, Sedelies K, Ciccone A, Anthony D, et al. Residual active granzyme B in cathepsin C-null lymphocytes is sufficient for perforin-dependent target cell apoptosis. J Cell Biol. 2007;176(4):425-33.
66. Ondr JK, Pham CT. Characterization of murine cathepsin W and its role in cell-mediated cytotoxicity. J Biol Chem. 2004;279(26):27525-33. (Pubitemid 38812593)
67. Michallet M-C, Saltel F, Preville X, Flacher M, Revillard J-P, Genestier L. Cathepsin B-dependent apoptosis triggered by antithymocyte globulins: a novel mechanism of T-cell depletion. Blood. 2003;102(10):3719-26. (Pubitemid 37409393)
68. Michallet M-C, Saltel F, Flacher M, Revillard J-P, Genestier L. Cathepsin-dependent apoptosis triggered by supraoptimal activation of T lymphocytes: a possible mechanism of high dose tolerance. J Immunol. 2004;172(9):5405-14. (Pubitemid 38542040)
69. Kishimoto H, Sprent J. Strong TCR ligation without costimulation causes rapid onset of Fas-dependent apoptosis of naive murine CD4+ T cells. J Immunol. 1999;163(4):1817-26. (Pubitemid 29382180)
70. Alexander-Miller MA, Leggatt GR, Sarin A, Berzofsky JA. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med. 1996;184(2):485-92. (Pubitemid 26324102)
71. van Eijk M, de Groot C. Germinal center B cell apoptosis requires both caspase and cathepsin activity. J Immunol. 1999;163(5):2478-82.
72. van Nierop K, Muller FJ, Stap J, Van Noorden CJ, van Eijk M, de Groot C. Lysosomal destabilization contributes to apoptosis of germinal center B-lymphocytes. J Histochem Cytochem. 2006;54(12):1425-35. (Pubitemid 44788827)
73. Laforge M, Petit F, Estaquier J, Senik A. Commitment to apoptosis in CD4+ T lymphocytes productively infected with human immunodeficiency virus type 1 is initiated by lysosomal membrane permeabilization, itself induced by the isolated expression of the viral protein Nef. J Virol. 2007;81(20):11426-40. (Pubitemid 47536113)
74. Reddy VY, Zhang QY, Weiss SJ. Pericellular mobilization of the tissuedestructive cysteine proteases, cathepsin B, L and S, by human monocyte-derived macrophages. Proc Natl Acad Sci. USA 1995;92(9):3849-53.
75. Thurmond RL, Sun S, Karlsson L, Edwards JP. Cathepsin S inhibitors as novel immunomodulators. Curr Opin Investig Drugs. 2005;6(5):473-82. (Pubitemid 40613968)
76. Pierre P, Mellman I. Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell. 1998;93(7):1135-45. (Pubitemid 28307419)
77. Roth W, Deussing JA, Botchkarev VA, Pauly-Evers M, Saftig P, Hafner A, et al. Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J. 2000;14(13):2075-86.
78. Hagemann S, Günther T, Dennemärker J, Lohmüller T, Brömme D, Schüle R, et al. The human cysteine protease cathepsin V can compensate for murine cathepsin L in mouse epidermis and hair follicles. Eur J Cell Biol. 2004;83(11-12):775-80. (Pubitemid 40123841)
79. Stypmann J, Gläser K, Roth W, Tobin DJ, Petermann I, Matthias R, et al. Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci. USA 2002;99(9):6234-9. (Pubitemid 34493295)
80. Liu J, Sukhova GK, Yang J-T, Sun J, Ma L, Ren A, et al. Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis. 2006;184(2):302-11. (Pubitemid 43049714)
81. Kitamoto S, Sukhova GK, Sun J, Yang M, Libby P, Love V, et al. Cathepsin L deficiency reduces diet-induced atherosclerosis in lowdensity lipoprotein receptor-knockout mice. Circulation. 2007;115(15):2065-75. (Pubitemid 46625958)
82. Sevenich L, Pennacchio LA, Peters C, Reinheckel T. Human cathepsin L rescues the neurodegeneration and lethality in cathepsin B/L doubledeficient mice. Biol Chem. 2006;387(7):885-91. (Pubitemid 44100235)
83. Everts V, Korper W, Hoeben KA, Jansen ID, Bromme D, Cleutjens KB, et al. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res. 2006;21(9):1399-408. (Pubitemid 44300046)
84. Tsukuba T, Okamoto K, Okamoto Y, Yanagawa M, Kohmura K, Yasuda Y, et al. Association of cathepsin E deficiency with development of atopic dermatitis. J Biochem. 2003;134(6): 893-902. (Pubitemid 38248365)
85. Henningsson F, Yamamoto K, Saftig P, Reinheckel T, Peters C, Knight SD, et al. A role for cathepsin E in the processing of mast-cell carboxypeptidase A. J Cell Sci. 2005;118(9):2035-42. (Pubitemid 40723846)
86. Yasuda Y, Kaleta J, Brömme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev. 2005;57(7):973-93. (Pubitemid 40703885)
87. Grabowska U, Chambers TJ, Shiroo M. Recent development in cathepsin K inhibitor design. Curr Opin Drug Discov Devel. 2005;8(5):619-30. (Pubitemid 41224125)
88. Siintola E, Partanen S, Stromme P, Haapanen A, Haltia M, Maehlen J, et al. Cathepsin D deficiency underlies congenital human neuronal ceroidlipofuscinosis. Brain. 2006;129(6):1438-45. (Pubitemid 43999376)
89. Steinfeld R, Reinhardt K, Schreiber K, Hillebrand M, Kraetzner R, Brück W, et al. Cathepsin D deficiency is associated with a human neurodegenerative disorder. Am J Hum Genet. 2006;78(6):988-98. (Pubitemid 43787690)
90. Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron. 2006;51(6):703-14. (Pubitemid 44374903)
91. Benes P, Vetvicka V, Fusek M. Cathepsin D - many functions of one aspartic protease. Crit Rev Oncol Hematol. 2008;68(1):12-28.
92. Pagano MB, Bartoli MA, Ennis TL, Mao D, Simmons PM, Thompson RW, et al. Critical role of dipeptidyl peptidase I in neutrophil recruitment during the development of experimental abdominal aortic aneurysms. Proc Natl Acad Sci. 2007;104(8):2855-60. (Pubitemid 46327969)
93. Hu Y, Pham CT. Dipeptidyl peptidase I regulates the development of collagen-induced arthritis. Arthritis Rheum. 2005;52(8):2553-8. (Pubitemid 41117445)
94. Pham CT, Ivanovich JL, Raptis SZ, Zehnbauer B, Ley TJ. Papillon-Lefèvre syndrome: correlating the molecular, cellular, and clinical consequences of cathepsin C/dipeptidyl peptidase I deficiency in humans. J Immunol. 2004;173(12):7277-81. (Pubitemid 39628164)
95. Jäättelä M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene. 2004;23(16):2746-56. (Pubitemid 38638838)
96. Kirkegaard T, Jäättelä M. Lysosomal involvement in cell death and cancer. Biochem Biophys Acta. 2009;1793(4):746-54.
97. Pennacchio LA, Lehesjoki AE, Stone NE, Willour VL, Virtaneva K, Miao J, et al. Mutations in the gene encoding cystatin B in progressive myoclonous epilepsy (EPM1). Science. 1996;271(5256):1731-4. (Pubitemid 26102822)
98. Pennacchio LA, Bouley DM, Higgins KM, Scott MP, Noebels JL, Myers RM. Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nat Genet. 1998;20(3):251-8. (Pubitemid 28507669)
99. Farina F, Cappello F, Todaro M, Bucchieri F, Peri G, Zummo G, et al. Involvement of caspase-3 and GD3 ganglioside in ceramide-induced apoptosis in Farber disease. J Histochem Cytochem. 2000;48(1):57-62. (Pubitemid 30053566)